Current approaches to systemic treatment of <i>BRCA</i>-associated triple-negative breast cancer
BRCA-associated triple-negative breast cancer (TNBC) is characterized by high sensitivity to DNA-damaging cytotoxic drugs. The use of well-known BRCA1/2-specific antitumor agents – platinum derivatives and PARP inhibitors – has been discussed for a long time in the context of the treatment of metast...
Saved in:
| Main Authors: | D. A. Enaldieva, P. V. Krivorotko, E. N. Imyanitov, E. K. Zhiltsova, R. V. Donskikh, L. F. Shaikhelislamova, L. P. Gigolaeva, V. F. Semiglazov |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
ABV-press
2023-10-01
|
| Series: | Успехи молекулярной онкологии |
| Subjects: | |
| Online Access: | https://umo.abvpress.ru/jour/article/view/564 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The role of platinum-based antineoplastic drugs and their impact on complete pathological response and prognosis in patients with BRCA-associated triple-negative breast cancer after neoadjuvant treatment: a single institution experience
by: D. A. Enaldieva, et al.
Published: (2023-06-01) -
Comparison of outcomes of neoadjuvant chemotherapy in BRCA1- versus BRCA2-associated breast and ovarian cancers
by: Anna Sokolenko, et al.
Published: (2025-06-01) -
COMPARATIVE ANALYSIS OF DIFFERENT NEOADJUVANT CHEMOTHERAPY REGIMENS FOR TRIPLE-NEGATIVE BREAST CANCER
by: P. V. Krivorotko, et al.
Published: (2017-12-01) -
Pattern Anlysis of Risk-Reducing Strategies in Unaffected Korean <i>BRCA1/2</i> Mutation Carriers
by: Dabin Kim, et al.
Published: (2024-11-01) -
Druggable Molecular Networks in <i>BRCA1/BRCA2</i>-Mutated Breast Cancer
by: Francesca Pia Carbone, et al.
Published: (2025-03-01)